Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itaru Hashimoto

Showing results (121-130 of 128) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 128 results.
Anticancer Research|November 1, 2023
The C-reactive Protein to Prealbumin Ratio Is an Independent Prognostic Factor for Patients With Gastric Cancer Who Receive Curative SurgeryToru Aoyama, Itaru Hashimoto, Yukio Maezawa, et al.
Anticancer Research|November 29, 2023
The Clinical Influence of Geriatric Nutritional Risk Index in Patients With Gastric Cancer Who Receive Curative TreatmentToru Aoyama, Yukio Maezawa, Itaru Hashimoto, et al.
In Vivo (Athens, Greece)|February 28, 2024
The Naples Prognostic Score Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative TreatmentToru Aoyama, Aya Kato, Itaru Hashimoto, et al.
In Vivo (Athens, Greece)|August 19, 2021
Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric CancerKenki Segami, Toru Aoyama, Yukihiko Hiroshima, et al.
Anticancer Research|July 7, 2021
Clinical Significance of <i>PLA2G2A</i> Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1Shinsuke Hatori, Kentaro Sakamaki, Takehiko Yokohori, et al.
In Vivo (Athens, Greece)|December 29, 2019
Impact of the <i>ESM-1</i> Gene Expression on Outcomes in Stage II/III Gastric Cancer Patients Who Received Adjuvant S-1 ChemotherapyKazuki Kano, Kentaro Sakamaki, Naohide Oue, et al.
Anticancer Research|December 8, 2019
Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug TherapyMasataka Oneyama, Naoya Sakamoto, Naohide Oue, et al.
Cancer Science|September 22, 2022
Nucleic acid-triggered tumoral immunity propagates pH-selective therapeutic antibodies through tumor-driven epitope spreadingGenta Furuya, Hiroto Katoh, Shinichiro Atsumi, et al.
Pageof 13

Showing results (121-130 of 128) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 128 results.
Anticancer Research|November 1, 2023
The C-reactive Protein to Prealbumin Ratio Is an Independent Prognostic Factor for Patients With Gastric Cancer Who Receive Curative SurgeryToru Aoyama, Itaru Hashimoto, Yukio Maezawa, et al.
Anticancer Research|November 29, 2023
The Clinical Influence of Geriatric Nutritional Risk Index in Patients With Gastric Cancer Who Receive Curative TreatmentToru Aoyama, Yukio Maezawa, Itaru Hashimoto, et al.
In Vivo (Athens, Greece)|February 28, 2024
The Naples Prognostic Score Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative TreatmentToru Aoyama, Aya Kato, Itaru Hashimoto, et al.
In Vivo (Athens, Greece)|August 19, 2021
Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric CancerKenki Segami, Toru Aoyama, Yukihiko Hiroshima, et al.
Anticancer Research|July 7, 2021
Clinical Significance of <i>PLA2G2A</i> Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1Shinsuke Hatori, Kentaro Sakamaki, Takehiko Yokohori, et al.
In Vivo (Athens, Greece)|December 29, 2019
Impact of the <i>ESM-1</i> Gene Expression on Outcomes in Stage II/III Gastric Cancer Patients Who Received Adjuvant S-1 ChemotherapyKazuki Kano, Kentaro Sakamaki, Naohide Oue, et al.
Anticancer Research|December 8, 2019
Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug TherapyMasataka Oneyama, Naoya Sakamoto, Naohide Oue, et al.
Cancer Science|September 22, 2022
Nucleic acid-triggered tumoral immunity propagates pH-selective therapeutic antibodies through tumor-driven epitope spreadingGenta Furuya, Hiroto Katoh, Shinichiro Atsumi, et al.
Pageof 13